AstraZeneca PLC (NASDAQ:AZN) is Altrius Capital Management Inc’s 9th Largest Position

Altrius Capital Management Inc cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 108,790 shares of the company’s stock after selling 3,424 shares during the quarter. AstraZeneca accounts for about 2.1% of Altrius Capital Management Inc’s portfolio, making the stock its 9th largest holding. Altrius Capital Management Inc’s holdings in AstraZeneca were worth $8,476,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC increased its holdings in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after purchasing an additional 133 shares in the last quarter. Bruce G. Allen Investments LLC boosted its stake in AstraZeneca by 19.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after purchasing an additional 138 shares during the last quarter. Carnegie Investment Counsel boosted its stake in AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after purchasing an additional 138 shares during the last quarter. Crumly & Associates Inc. boosted its stake in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after purchasing an additional 143 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 2.0 %

AZN traded down $1.32 on Friday, hitting $63.72. The company had a trading volume of 1,692,619 shares, compared to its average volume of 5,248,717. The firm has a market cap of $197.57 billion, a P/E ratio of 31.12, a PEG ratio of 1.21 and a beta of 0.47. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company’s fifty day moving average price is $75.43 and its 200 day moving average price is $78.29. The company has a current ratio of 0.93, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.87 EPS. As a group, equities analysts expect that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. TD Cowen lifted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.